Boston Common Asset Management, LLC
Source: SEC Form 13F · as of Mar 2026Boston Common Asset Management, LLC holds 12 biotech & pharma companies tracked by BioSniper, totaling $125.4M in value as of Mar 2026 (SEC Form 13F).
Companies held
12
Total value held
$125.4M
| Company | Shares | Value |
|---|---|---|
| MRKMerck & Co., Inc. | 198,680 | $23.9M |
| LLYELI LILLY & Co | 24,353 | $22.4M |
| DGXQuest Diagnostics Incorporated | 90,326 | $17.7M |
| NVSNovartis AG | 108,116 | $16.5M |
| GILDGILEAD SCIENCES, INC. | 77,243 | $10.8M |
| AMGNAMGEN INC | 29,640 | $10.4M |
| AZNASTRAZENECA PLC | 40,960 | $8.1M |
| VRTXVERTEX PHARMACEUTICALS INC / MA | 17,205 | $7.7M |
| ABTABBOTT LABORATORIES | 41,309 | $4.2M |
| ARGXARGENX SE | 3,753 | $2.7M |
| RDYDR REDDYS LABORATORIES LTD | 53,275 | $738K |
| GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 3,804 | $210K |
13F holdings reflect long positions in U.S.-listed securities as reported to the SEC. Values are point-in-time for the most recent reported quarter.